Claire McDonald, Craig Alderson, Matthew G Birkbeck, Laura Brown, Silvia Del Din, Grainne G Gorman, Kieren Hollingsworth, Clare Massarella, Rana Rehman, Lynn Rochester, Avan Ap Sayer, Huizhong Su, Helen Tuppen, Charlotte Warren, Miles D Witham
INTRODUCTION: Sarcopenia is the age-associated loss of muscle mass and strength. Nicotinamide adenine dinucleotide (NAD) plays a central role in both mitochondrial function and cellular ageing processes implicated in sarcopenia. NAD concentrations are low in older people with sarcopenia, and increasing skeletal muscle NAD concentrations may offer a novel therapy for this condition. Acipimox is a licensed lipid-lowering agent known to act as an NAD precursor. This open-label, uncontrolled, before-and-after proof-of-concept experimental medicine study will test whether daily supplementation with acipimox improves skeletal muscle NAD concentrations...
February 27, 2024: BMJ Open